Clinical trials: Hepatic Fibrosis
Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001 compared with placebo, in Non-alcoholic Steatohepatitis…
- Trial name
- NCT04048876
- Testing
- CC-90001
- Where
- 142 sites in United States, Australia and 8 more
- Volunteers
- 56 people
- Sponsor
- Celgene
NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease
- Trial name
- AMBITION (NCT04480710)
- Testing
- CRV431 75mg, CRV431 225mg
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 47 people
- Sponsor
- Hepion Pharmaceuticals, Inc.
NASH - Nonalcoholic Steatohepatitis, Cirrhosis
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
To validate the ability of the Methacetin Breath Test (MBT) to detect clinically significant portal hypertension (CSPH)/severe portal hypertension (SPH) defined as hepatic venous pressure gradient (HVPG) ≥ 10 mmHg and HVPG ≥ 12…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Portal Hypertension
- Trial name
- NCT03439189
- Testing
- Methacetin Breath Test, Emricasan
- Where
- France
- Volunteers
- 343 people
- Sponsor
- Meridian Bioscience, Inc.
Chronic Hepatitis B With Hepatic Fibrosis
A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis
This is a single-arm, multicenter, open-label Phase III clinical trial to evaluate the safety and tolerability of high-dose hydronidone capsules in patients with hepatic fibrosis and cirrhosis.
- Trial name
- NCT07343778
- Testing
- Hydronidone Capsules
- Where
- China
- Volunteers
- 337 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hepatic Impairment, Cirrhosis
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of…
- Trial name
- NCT05484206
- Testing
- VIR-2218, VIR-3434
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Esophageal and/or Gastric Varices
Efficacy and Safety of Endoscopic Injection of Fibrin Sealant Versus Endoscopic Ligature for Bleeding Esophageal Varices
The purpose of this study was to assess whether endoscopic sclerotherapy with Fibrin Sealant was superior to ligature, with or without Polidocanol, in achieving hemostasis in bleeding esophageal varices and preventing rebleeding.
- Trial name
- NCT00161915
- Testing
- Fibrin Sealant
- Where
- 12 sites in Germany
- Sponsor
- Baxter Healthcare Corporation
Chronic Hepatitis B-related Liver Fibrosis
[¹⁴C] Hydronidone Mass Balance Study
According to the "Technical Guidelines for Radioactive Labeled Human Mass Balance Studies" issued by the NMPA, human mass balance studies are an important component of clinical pharmacology research for innovative drugs, and it…
- Trial name
- NCT07471217
- Testing
- [¹⁴C]Hydronidone
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.
- Conditions
- Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis
- Trial name
- TESA-LIVER (NCT07481734)
- Testing
- Tesamorelin, Standardized lifestyle counseling
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hudson Biotech
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.
- Trial name
- MAESTRO-NAFLD1 (NCT04197479)
- Testing
- Resmetirom
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 1,343 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Portal Hypertension
Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure
Chronic liver diseases are often characterized by portal hypertension, a major complication involving haemodynamic changes due to increased intrahepatic vascular resistance.
- Trial name
- NCT00414869
- Testing
- NCX-1000
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- Forest Laboratories
Liver Fibrosis/NASH
A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body
The purpose of this study is to assess safety, to measure blood levels of drug, and to find out what the drug does to the body.
- Trial name
- NCT02538874
- Testing
- BMS-986171
- Where
- 2 sites in United States
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Liver Fibroses
SWE Liver Stiffness as a Predictor of Progression of Chronic Liver Diseases
This study is a multicenter individual patient-based meta-analysis that will assess the performances of liver stiffness measurements performed with supersonic shear imaging shearwave elastography (SSI-SWE) in patients with liver…
- Trial name
- SWE Predict (NCT03389152)
- Testing
- Elastography
- Volunteers
- 2,148 people
- Sponsor
- SuperSonic Imagine
Alcoholic Liver Cirrhosis
Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis
This study will evaluate the safety and efficacy of mesenchymal stem cells in patients with cirrhosis of liver. Stem cells will be injected into the hepatic artery. Improvement in various parameters will be observed over 2 years.
- Trial name
- NCT01591200
- Testing
- Allogeneic Mesenchymal Stem Cells
- Where
- 10 sites in India
- Volunteers
- 40 people
- Sponsor
- Stempeutics Research Pvt Ltd
Hypoalbuminemia, Hepatic Cirrhosis
A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia
The goal of this clinical trial is to evaluate the efficacy of OsrHSA works to treat hypoalbuminemia in hepatic cirrhosis patients. It will also learn about the safety and immunogenicity of OsrHSA.
- Trial name
- NCT06355479
- Testing
- OsrHSA, Plasbumin®-20
- Where
- 37 sites in China
- Volunteers
- 328 people
- Sponsor
- Healthgen Biotechnology Corp.
Liver Fibrosis, Hepatic Cirrhosis
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.
- Trial name
- BRAVO (NCT07610837)
- Testing
- AZD2389
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Cirrhosis
A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema
OPC-41061 at 3.75 mg/day or 7.5 mg/day will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and pharmacodynamics, pharmacokinetics…
- Trial name
- NCT01114828
- Testing
- OPC-41061
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Nonalcoholic Steatohepatitis
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
The purpose of this study is to determine whether cenicriviroc is effective and safe in the treatment of nonalcoholic steatohepatitis (NASH) in adult participants with liver fibrosis.
- Trial name
- CENTAUR (NCT02217475)
- Testing
- Cenicriviroc
- Where
- 91 sites in United States, Australia and 8 more
- Volunteers
- 289 people
- Sponsor
- Tobira Therapeutics, Inc.
Chronic Hepatitis b, Liver Inflammation
Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B
This study evaluates the addition of glycyrrhizin to entecavir in the treatment of patients with chronic hepatitis B in China. Half of participants will receive magnesium isoglycyrrhizinate followed by oral diammonium…
- Trial name
- MAGIC-101 (NCT03349008)
- Testing
- Entecavir, Magnesium Isoglycyrrhizinate, Diammonium Glycyrrhizinate
- Volunteers
- 480 people
- Sponsor
- Cttq
Hepatobiliary Disorders, Non-alcoholic Fatty Liver Disease
A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
This study is looking at the effect of semaglutide on subjects with nonalcoholic fatty liver disease.This study is comparing the change in early stages of scar tissue in the liver and fat deposition in the liver in people taking…
- Trial name
- NCT03357380
- Testing
- Semaglutide
- Where
- 2 sites in Germany
- Volunteers
- 67 people
- Sponsor
- Novo Nordisk A/S
Hepatic Encephalopathy
Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.
- Trial name
- NCT01846663
- Testing
- Rifaximin
- Where
- 28 sites in United States
- Volunteers
- 6 people
- Sponsor
- Bausch Health Americas, Inc.